# Mepo for Eosinophilic Esophagitis (EoE) Study

> **NCT03656380** · PHASE2 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 66 (actual)

## Conditions studied

- EoE
- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Mepolizumab 300 mg
- **DRUG:** Mepolizumab 100 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03656380
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2022-06-06
- **Final completion:** 2022-12-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-08-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656380, "Mepo for Eosinophilic Esophagitis (EoE) Study". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT03656380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*